Navigation Links
Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
Date:12/6/2010

interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts.  You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning.  Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission.  Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect.  Therefore, you should not rely on any such factors or forward-looking statements.  Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law.  The Private Securities Litigation Reform Act of 1995 permits this discussion.Contacts:MediaFritz Bittenbender610-883-5855fbittenb@cephalon.comInvestorsRobert (Chip) Merritt 610-738-6376cmerritt@cephalon.com
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , SAN MATEO, Calif., Nov. 6 , ... of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd. ... Expanded management team to include VP Sales; Senior Director, Marketing; ... board as director and Audit Committee chairman , ...
... Therapeutics, Inc. delivered two presentations today on its ITCA ... treatment of type 2 diabetes at the Ninth Annual ... http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , Continuous Subcutaneous Delivery ... and Reduces Weight in a 28-day Phase 1b Study ...
... Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ) today ... 2009. GenVec reported a net loss of $3.6 million ($0.04 per ... a net loss of $6.8 million ($0.08 per share) in the ... 2009, GenVec,s net loss was $14.1 million ($0.15 per share), compared ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/25/2014)... the first broad-scale estimate of air pollution removal by ... that trees are saving more than 850 human lives ... symptoms. , While trees, pollution removal equated to an ... the impacts of that improvement are substantial. Researchers valued ... at nearly $7 billion every year in a study ...
(Date:7/25/2014)... on the land now called California, and many of ... plants they used for food, fuel, tools, and ritual. ... habitat and natural resources. , Frank Lake, an ecologist ... lead a field trip to the Stone ... America,s 99th Annual Meeting, in Sacramento, Cal. this August. ...
(Date:7/25/2014)... false-color image from the Terra satellite show the different areas ... in Eastern Russia. The burn scars show up as ... wildfires have broken across the remote parts of Eastern Russia ... from the MODIS instrument, it is still possible to ... recent image features noted below show the devastating number of ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... on the tap to get a glass of water, we just ... really safe? And, what exactly is "safe"? The public ... Marylynn Yates , a professor of environmental microbiology at the University ... will help the audience become familiar with the most common causes ...
... and clean people,s water supplies while serving as important ... cranes and alligators. Conventional ecosystem health assessments have focused ... unseen creatures in the wetlands provided crucial indicators of ... Missouri Associate Professor of Engineering Zhiqiang Hu and his ...
... GSA Bulletin articles posted online ahead of ... in central Asia; (2) crystal xenoliths in the Bolivian Altiplano; ... Group contact, Barberton greenstone belt, South Africa; (5) iron oxide ... Alaska syntaxis; (7) paleotopography of the South Norwegian margin; and ...
Cached Biology News:How safe is our drinking water? 2Measuring microbes makes wetland health monitoring more affordable, says MU researcher 2Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 2Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 3Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 4Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 5Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 6Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 7Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 8Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 9
...
... Vacuum pumps deliver critical performance for all ... control optimizes pump performance to suit all ... for convenient checking of proper oil levels ... pumps is designed to work with all ...
... The IITC Life Science Rotarods are used ... motor coordination or fatigue resistance on mice and ... humane way. Extremely user friendly; the animals are ... an animal drops onto the individual sensing platforms ...
... Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a ... PGF2α), in rabbits, monkeys and humans. ... of non-specific lipid peroxidation. In both ... is converted primarily to metabolites having ...
Biology Products: